Latest RMD news

ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand

MarketBeat · Mon, 21 Sep 2026 16:02:23 -0400

ResMed NYSE: RMD outlined its growth outlook, margin strategy and portfolio plans during a Morgan Stanley discussion, with executives emphasizing demand generation, patient adherence and ongoing product innovation in sleep and respiratory care.

Sleep Device Maker ResMed Gets an Upgrade. Analysts See a Lot to Like.

Barrons · Tue, 15 Sep 2026 16:07:00 -0400

Setbacks for competitors have positioned ResMed to capture more market share.

ResMed Inc. (RMD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · Tue, 15 Sep 2026 13:11:47 -0400

ResMed Inc. (RMD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Is This the Right Time to Retain Resmed Stock in Your Portfolio?

Zacks Investment Research · Tue, 15 Sep 2026 11:10:56 -0400

RMD's software portfolio optimization, mask innovation and solid financial health support growth, though macro pressures and competition pose risks.

Top 50 High-Quality Dividend Growth Stocks For September 2026

Seeking Alpha · Sun, 13 Sep 2026 23:54:39 -0400

I track a universe of 50 high-quality dividend growth stocks to identify opportune entry points based on valuation and future return potential. Recent upgrades include Eli Lilly, Watsco, and Nike, driven by improved valuations and stronger EPS growth projections. 43 out of 50 stocks currently offer a forward return estimate of at least 10%, with 29 appearing potentially undervalued based on free cash flow mean reversion.

ResMed: A Significant Upside Despite The Perceived Risk

Seeking Alpha · Thu, 10 Sep 2026 07:18:33 -0400

ResMed has de-rated from 30x to under 21x earnings despite 17% EPS growth, driven by narrative rather than fundamentals. Recurring mask and consumables revenue, now 42% of the sleep and breathing segment, is underappreciated and grew 13% last year. Two major risks—sleep apnea pill and reimbursement—are less material for RMD than feared; Philips' US return poses the most credible threat.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD

PRNewsWire · Thu, 03 Sep 2026 10:00:00 -0400

NEW YORK, Sept. 3, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ResMed Inc. ("ResMed" or the "Company") (NYSE: RMD).

Market information is provided for research and visualization and is not investment advice.